Amarin Corp. PLC (AMRN) Reaches New 52-Week High at $3.46
Shares of Amarin Corp. PLC (NASDAQ:AMRN) hit a new 52-week high during trading on Monday . The company traded as high as $3.46 and last traded at $3.21, with a volume of 2,484,294 shares trading hands. The stock had previously closed at $3.33.
AMRN has been the subject of a number of analyst reports. Zacks Investment Research upgraded Amarin Corp. PLC from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a research report on Thursday, August 4th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Amarin Corp. PLC in a research report on Monday, May 9th. Finally, Jefferies Group restated a “buy” rating on shares of Amarin Corp. PLC in a research report on Wednesday, June 8th.
The firm’s market capitalization is $614.29 million. The firm has a 50 day moving average price of $2.43 and a 200 day moving average price of $1.86.
Amarin Corp. PLC (NASDAQ:AMRN) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. During the same quarter in the prior year, the company earned ($0.15) earnings per share. The business earned $32.82 million during the quarter, compared to the consensus estimate of $29.97 million. Amarin Corp. PLC’s revenue was up 85.4% compared to the same quarter last year. Analysts anticipate that Amarin Corp. PLC will post ($0.53) EPS for the current year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.